Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration
LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenou...
Gespeichert in:
| Veröffentlicht in: | Journal of medicinal chemistry 2020-01, Vol.63 (1), p.88-102 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 1 |
| container_start_page | 88 |
| container_title | Journal of medicinal chemistry |
| container_volume | 63 |
| creator | Panchaud, Philippe Surivet, Jean-Philippe Diethelm, Stefan Blumstein, Anne-Catherine Gauvin, Jean-Christophe Jacob, Loïc Masse, Florence Mathieu, Gaëlle Mirre, Azely Schmitt, Christine Enderlin-Paput, Michel Lange, Roland Gnerre, Carmela Seeland, Swen Herrmann, Charlyse Locher, Hans H Seiler, Peter Ritz, Daniel Rueedi, Georg |
| description | LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models. |
| doi_str_mv | 10.1021/acs.jmedchem.9b01605 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_31804829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322720136</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-5e11a31729aeed2808658878507f8b9e9753006a9819b2731a5f2674257a884e3</originalsourceid><addsrcrecordid>eNqNkUFP3DAQha2qVdnS_oOq8rFSle3YjhPniAIUpJW4wDlyHJs12thpnBQof55ZsnCserLl-d7M8xtCvjJYM-DspzZpfdfbzmxtv65aYAXId2TFJIcsV5C_JysAzjNecHFEPqV0BwCCcfGRHAmGgOLVijxdDZPv_V89-RhodHQzPNT0Mmx966c40o3VHa1jP8Q5dImeRzMnH24pwmfOeaPNI9Whw8LYz7uli0Pdhb_d0tOYLPaaRv3HhjgnetL1PviED3vwM_ng9C7ZL4fzmNycn13XF9nm6tdlfbLJtMjVlEnLmBas5JW2tuMKVCGVKpWE0qm2slUpBUChK8WqlpeCael4UeZcllqp3Ipj8n3pO4zx92zT1PQ-Gbvb6WDRVcMF5yUHJgpE8wU1Y0xptK4ZRt_r8bFh0OxjbzD25jX25hA7yr4dJswt1t5Erzkj8GMB7m0bXTLeBmPfMFwMfoZJyPEGexfq_-naTy9p1rihCaWwSF98xnkMmOy_zT8DWn2yaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322720136</pqid></control><display><type>article</type><title>Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration</title><source>ACS Publications</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Panchaud, Philippe ; Surivet, Jean-Philippe ; Diethelm, Stefan ; Blumstein, Anne-Catherine ; Gauvin, Jean-Christophe ; Jacob, Loïc ; Masse, Florence ; Mathieu, Gaëlle ; Mirre, Azely ; Schmitt, Christine ; Enderlin-Paput, Michel ; Lange, Roland ; Gnerre, Carmela ; Seeland, Swen ; Herrmann, Charlyse ; Locher, Hans H ; Seiler, Peter ; Ritz, Daniel ; Rueedi, Georg</creator><creatorcontrib>Panchaud, Philippe ; Surivet, Jean-Philippe ; Diethelm, Stefan ; Blumstein, Anne-Catherine ; Gauvin, Jean-Christophe ; Jacob, Loïc ; Masse, Florence ; Mathieu, Gaëlle ; Mirre, Azely ; Schmitt, Christine ; Enderlin-Paput, Michel ; Lange, Roland ; Gnerre, Carmela ; Seeland, Swen ; Herrmann, Charlyse ; Locher, Hans H ; Seiler, Peter ; Ritz, Daniel ; Rueedi, Georg</creatorcontrib><description>LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.9b01605</identifier><identifier>PMID: 31804829</identifier><language>eng</language><publisher>WASHINGTON: American Chemical Society</publisher><subject>Chemistry, Medicinal ; Life Sciences & Biomedicine ; Pharmacology & Pharmacy ; Science & Technology</subject><ispartof>Journal of medicinal chemistry, 2020-01, Vol.63 (1), p.88-102</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>13</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000507150400006</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-a348t-5e11a31729aeed2808658878507f8b9e9753006a9819b2731a5f2674257a884e3</citedby><cites>FETCH-LOGICAL-a348t-5e11a31729aeed2808658878507f8b9e9753006a9819b2731a5f2674257a884e3</cites><orcidid>0000-0002-3505-2025 ; 0000-0001-7823-7639</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01605$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01605$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>315,781,785,2766,27081,27929,27930,28253,56743,56793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31804829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Panchaud, Philippe</creatorcontrib><creatorcontrib>Surivet, Jean-Philippe</creatorcontrib><creatorcontrib>Diethelm, Stefan</creatorcontrib><creatorcontrib>Blumstein, Anne-Catherine</creatorcontrib><creatorcontrib>Gauvin, Jean-Christophe</creatorcontrib><creatorcontrib>Jacob, Loïc</creatorcontrib><creatorcontrib>Masse, Florence</creatorcontrib><creatorcontrib>Mathieu, Gaëlle</creatorcontrib><creatorcontrib>Mirre, Azely</creatorcontrib><creatorcontrib>Schmitt, Christine</creatorcontrib><creatorcontrib>Enderlin-Paput, Michel</creatorcontrib><creatorcontrib>Lange, Roland</creatorcontrib><creatorcontrib>Gnerre, Carmela</creatorcontrib><creatorcontrib>Seeland, Swen</creatorcontrib><creatorcontrib>Herrmann, Charlyse</creatorcontrib><creatorcontrib>Locher, Hans H</creatorcontrib><creatorcontrib>Seiler, Peter</creatorcontrib><creatorcontrib>Ritz, Daniel</creatorcontrib><creatorcontrib>Rueedi, Georg</creatorcontrib><title>Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration</title><title>Journal of medicinal chemistry</title><addtitle>J MED CHEM</addtitle><addtitle>J. Med. Chem</addtitle><description>LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models.</description><subject>Chemistry, Medicinal</subject><subject>Life Sciences & Biomedicine</subject><subject>Pharmacology & Pharmacy</subject><subject>Science & Technology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkUFP3DAQha2qVdnS_oOq8rFSle3YjhPniAIUpJW4wDlyHJs12thpnBQof55ZsnCserLl-d7M8xtCvjJYM-DspzZpfdfbzmxtv65aYAXId2TFJIcsV5C_JysAzjNecHFEPqV0BwCCcfGRHAmGgOLVijxdDZPv_V89-RhodHQzPNT0Mmx966c40o3VHa1jP8Q5dImeRzMnH24pwmfOeaPNI9Whw8LYz7uli0Pdhb_d0tOYLPaaRv3HhjgnetL1PviED3vwM_ng9C7ZL4fzmNycn13XF9nm6tdlfbLJtMjVlEnLmBas5JW2tuMKVCGVKpWE0qm2slUpBUChK8WqlpeCael4UeZcllqp3Ipj8n3pO4zx92zT1PQ-Gbvb6WDRVcMF5yUHJgpE8wU1Y0xptK4ZRt_r8bFh0OxjbzD25jX25hA7yr4dJswt1t5Erzkj8GMB7m0bXTLeBmPfMFwMfoZJyPEGexfq_-naTy9p1rihCaWwSF98xnkMmOy_zT8DWn2yaQ</recordid><startdate>20200109</startdate><enddate>20200109</enddate><creator>Panchaud, Philippe</creator><creator>Surivet, Jean-Philippe</creator><creator>Diethelm, Stefan</creator><creator>Blumstein, Anne-Catherine</creator><creator>Gauvin, Jean-Christophe</creator><creator>Jacob, Loïc</creator><creator>Masse, Florence</creator><creator>Mathieu, Gaëlle</creator><creator>Mirre, Azely</creator><creator>Schmitt, Christine</creator><creator>Enderlin-Paput, Michel</creator><creator>Lange, Roland</creator><creator>Gnerre, Carmela</creator><creator>Seeland, Swen</creator><creator>Herrmann, Charlyse</creator><creator>Locher, Hans H</creator><creator>Seiler, Peter</creator><creator>Ritz, Daniel</creator><creator>Rueedi, Georg</creator><general>American Chemical Society</general><general>Amer Chemical Soc</general><scope>1KM</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3505-2025</orcidid><orcidid>https://orcid.org/0000-0001-7823-7639</orcidid></search><sort><creationdate>20200109</creationdate><title>Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration</title><author>Panchaud, Philippe ; Surivet, Jean-Philippe ; Diethelm, Stefan ; Blumstein, Anne-Catherine ; Gauvin, Jean-Christophe ; Jacob, Loïc ; Masse, Florence ; Mathieu, Gaëlle ; Mirre, Azely ; Schmitt, Christine ; Enderlin-Paput, Michel ; Lange, Roland ; Gnerre, Carmela ; Seeland, Swen ; Herrmann, Charlyse ; Locher, Hans H ; Seiler, Peter ; Ritz, Daniel ; Rueedi, Georg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-5e11a31729aeed2808658878507f8b9e9753006a9819b2731a5f2674257a884e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemistry, Medicinal</topic><topic>Life Sciences & Biomedicine</topic><topic>Pharmacology & Pharmacy</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Panchaud, Philippe</creatorcontrib><creatorcontrib>Surivet, Jean-Philippe</creatorcontrib><creatorcontrib>Diethelm, Stefan</creatorcontrib><creatorcontrib>Blumstein, Anne-Catherine</creatorcontrib><creatorcontrib>Gauvin, Jean-Christophe</creatorcontrib><creatorcontrib>Jacob, Loïc</creatorcontrib><creatorcontrib>Masse, Florence</creatorcontrib><creatorcontrib>Mathieu, Gaëlle</creatorcontrib><creatorcontrib>Mirre, Azely</creatorcontrib><creatorcontrib>Schmitt, Christine</creatorcontrib><creatorcontrib>Enderlin-Paput, Michel</creatorcontrib><creatorcontrib>Lange, Roland</creatorcontrib><creatorcontrib>Gnerre, Carmela</creatorcontrib><creatorcontrib>Seeland, Swen</creatorcontrib><creatorcontrib>Herrmann, Charlyse</creatorcontrib><creatorcontrib>Locher, Hans H</creatorcontrib><creatorcontrib>Seiler, Peter</creatorcontrib><creatorcontrib>Ritz, Daniel</creatorcontrib><creatorcontrib>Rueedi, Georg</creatorcontrib><collection>Index Chemicus</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Panchaud, Philippe</au><au>Surivet, Jean-Philippe</au><au>Diethelm, Stefan</au><au>Blumstein, Anne-Catherine</au><au>Gauvin, Jean-Christophe</au><au>Jacob, Loïc</au><au>Masse, Florence</au><au>Mathieu, Gaëlle</au><au>Mirre, Azely</au><au>Schmitt, Christine</au><au>Enderlin-Paput, Michel</au><au>Lange, Roland</au><au>Gnerre, Carmela</au><au>Seeland, Swen</au><au>Herrmann, Charlyse</au><au>Locher, Hans H</au><au>Seiler, Peter</au><au>Ritz, Daniel</au><au>Rueedi, Georg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration</atitle><jtitle>Journal of medicinal chemistry</jtitle><stitle>J MED CHEM</stitle><addtitle>J. Med. Chem</addtitle><date>2020-01-09</date><risdate>2020</risdate><volume>63</volume><issue>1</issue><spage>88</spage><epage>102</epage><pages>88-102</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models.</abstract><cop>WASHINGTON</cop><pub>American Chemical Society</pub><pmid>31804829</pmid><doi>10.1021/acs.jmedchem.9b01605</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-3505-2025</orcidid><orcidid>https://orcid.org/0000-0001-7823-7639</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2623 |
| ispartof | Journal of medicinal chemistry, 2020-01, Vol.63 (1), p.88-102 |
| issn | 0022-2623 1520-4804 |
| language | eng |
| recordid | cdi_pubmed_primary_31804829 |
| source | ACS Publications; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology |
| title | Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A46%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20LpxC%20Inhibitor%20Lead%20Compounds%20Focusing%20on%20Efficacy%20and%20Formulation%20for%20High%20Dose%20Intravenous%20Administration&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Panchaud,%20Philippe&rft.date=2020-01-09&rft.volume=63&rft.issue=1&rft.spage=88&rft.epage=102&rft.pages=88-102&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.9b01605&rft_dat=%3Cproquest_pubme%3E2322720136%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322720136&rft_id=info:pmid/31804829&rfr_iscdi=true |